| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
| US11639347 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(3 years from now) | |
| US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(3 years from now) | |
| US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(3 years from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(3 years from now) | |
| US11426407 | VERTEX PHARMS INC | NA |
Oct, 2035
(12 years from now) | |
| US10758534 | VERTEX PHARMS INC | NA |
Oct, 2035
(12 years from now) | |
| US11453655 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(14 years from now) | |
| US10793547 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(1 year, 8 months from now) | |
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(2 years from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
| US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(3 years from now) | |
| US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(3 years from now) | |
| US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(4 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
| US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(7 years from now) | |
| US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(7 years from now) | |
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(9 years from now) | |
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(9 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(9 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(9 years from now) | |
| US11179367 | VERTEX PHARMS INC | Pharmaceutical compositions for treating cystic fibrosis |
Dec, 2037
(14 years from now) | |
| US11517564 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Dec, 2037
(14 years from now) | |
Trikafta (Copackaged) is owned by Vertex Pharms Inc.
Trikafta (Copackaged) contains Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor.
Trikafta (Copackaged) has a total of 31 drug patents out of which 0 drug patents have expired.
Trikafta (Copackaged) was authorised for market use on 26 April, 2023.
Trikafta (Copackaged) is available in granules;oral dosage forms.
Trikafta (Copackaged) can be used as treatment of cf in patients aged 2 to <6 years who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data comprising administering a composition according to claim 1 of us 10272046, treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a composition according to at least one of claims 1-9 of us11179367, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor, treatment of cf in patients aged 2 to <6 years who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data using a solid composition comprising elx, tez, amorphous iva, and < ~30% crystalline iva, treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering daily elx (200 mg or 100 mg); tez; and iva, treatment of cystic fibrosis in patients aged 2 to <6 years who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor, treatment of cystic fibrosis in patients aged 2 to <6 years who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor, treatment of cf in patients aged 2 to <6 years who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data comprising administering a composition according to claim 1 of us 11147770, treatment of cf in patients aged 2 to <6 years who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data comprising administering the composition recited in us 11564916 claim 1, treatment of cystic fibrosis in patients aged 2 to <6 years who have in the cftr gene at least one f508del mutation or a responsive mutation based on in vitro data with an effective amount of elx, tez, and iva, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with an effective amount of elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with an effective amount of elx, tez, and iva; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with an effective amount of elx, tez, and iva, treatment of cystic fibrosis in patients aged 2 to <6 years who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a compound of claim 1 or composition of claim 29 of us 11426407, treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva; treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition according to claim 1 of us 10081621; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor, treatment of cf in patients aged 2 to <6 years who have in the cftr gene at least one f508del mutation or a responsive mutation based on in vitro data by administering elexacaftor, ivacaftor, and a solid dispersion of tezacaftor and a polymer.
Drug patent challenges can be filed against Trikafta (Copackaged) from 2023-10-22.
The generics of Trikafta (Copackaged) are possible to be released after 08 December, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 26, 2030 |
| New Chemical Entity Exclusivity (NCE) | Oct 21, 2024 |
| New Product (NP) | Apr 26, 2026 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 2023-10-22
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatm...
Dosage: GRANULES;ORAL
TRIKAFTA (COPACKAGED) family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic